Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.40 |
| ▸ | HTR2C | P28335 | 9/20 | 0.40 |
| ▸ | CCR3 | P51677 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7972099 | 0.99 | HTR2A (0.39) | HTR2AHTR2CCCR3HTR7KDM1A | |
| SCHEMBL7971786 | 0.92 | KMT2A (0.40) | CCR3KDM1AHTR4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7985629 | 0.91 | KMT2A (0.39) | CCR3KDM1AHTR4MEN1KMT2A | |
| SCHEMBL7983503 | 0.89 | KDM1A (0.42) | CCR3HTR7KDM1ADRD2HTR4 | |
| SCHEMBL7989275 | 0.89 | CCR3 (0.47) | CCR3KDM1ALTA4H | |
| SCHEMBL7986376 | 0.89 | HTR7 (0.43) | HTR2AHTR7KDM1AKCNH2HTR4 | |
| Hydrochloric Acid SCHEMBL7981947 | 0.89 | KDM1A (0.41) | CCR3HTR7KDM1ADRD2HTR4 | |
| Hydrochloric Acid SCHEMBL7986155 | 0.88 | CCR3 (0.47) | CCR3KDM1ALTA4H | |
| Hydrochloric Acid SCHEMBL7982153 | 0.88 | HTR7 (0.43) | HTR2AHTR7KDM1AKCNH2HTR4 | |
| SCHEMBL7985386 | 0.87 | HTR4 (0.42) | HTR2AHTR7KDM1ADRD2HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | METABASIS THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | METABASIS THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-6235731-B1 | REDUCING BLOOD LIPIDS, SUGARS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0915888-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | Takeda Chemical Industries, Ltd. (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | FBP1, G6PC1, IRS1 | HTR2A 4558/4885HTR2C 4734/4885CCR3 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.